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Abstract
Purpose
To compare human observers to a mathematically derived computer model for differentia-
tion between malignant and benign pulmonary nodules detected on baseline screening
computed tomography (CT) scans.
Methods
A case-cohort study design was chosen. The study group consisted of 300 chest CT scans
from the Danish Lung Cancer Screening Trial (DLCST). It included all scans with proven
malignancies (n = 62) and two subsets of randomly selected baseline scans with benign
nodules of all sizes (n = 120) and matched in size to the cancers, respectively (n = 118).
Eleven observers and the computer model (PanCan) assigned a malignancy probability
score to each nodule. Performances were expressed by area under the ROC curve (AUC).
Performance differences were tested using the Dorfman, Berbaum and Metz method.
Seven observers assessed morphological nodule characteristics using a predefined list. Dif-
ferences in morphological features between malignant and size-matched benign nodules
were analyzed using chi-square analysis with Bonferroni correction. A significant difference
was defined at p < 0.004.
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Results
Performances of the model and observers were equivalent (AUC 0.932 versus 0.910,
p = 0.184) for risk-assessment of malignant and benign nodules of all sizes. However,
human readers performed superior to the computer model for differentiating malignant nod-
ules from size-matched benign nodules (AUC 0.819 versus 0.706, p < 0.001). Large varia-
tions between observers were seen for ROC areas and ranges of risk scores. Morphological
findings indicative of malignancy referred to border characteristics (spiculation, p < 0.001)
and perinodular architectural deformation (distortion of surrounding lung parenchyma archi-
tecture, p < 0.001; pleural retraction, p = 0.002).
Conclusions
Computer model and human observers perform equivalent for differentiating malignant from
randomly selected benign nodules, confirming the high potential of computer models for
nodule risk estimation in population based screening studies. However, computer models
highly rely on size as discriminator. Incorporation of other morphological criteria used by
human observers to superiorly discriminate size-matched malignant from benign nodules,
will further improve computer performance.
Introduction
Lung cancer is the deadliest cancer in both men and women [1] because the disease is usually
diagnosed at an advanced stage. The National Lung Screening Trial (NLST) demonstrated a
decrease in lung cancer-specific mortality of 20% [2], which was the major driving power lead-
ing to a recommendation of low-dose computed tomography (CT) lung screening for eligible
subjects by several organizations including the U.S Preventative Services Task Force (USPSTF)
[3,4]. Lung cancer screening programs are now being implemented in the U.S.
Low-dose CT studies of the lung—obtained within a lung cancer screening program—are
characterized by the discrepancy between the high prevalence of pulmonary nodules and the
relatively low incidence of actual lung cancers. In the first CT round of the 24,715 subjects in
the CT arm of the NLST a total of 6,786 nodules had been annotated, however, only 168 sub-
jects were eventually diagnosed with a pulmonary malignancy within the 3 years screening
period or the follow-up of 6.5 years, illustrating the high prevalence of nodules in screening
CTs in general and the magnitude of the diagnostic and organizational challenge [5]. Accuracy
and efficiency of screening programs will therefore largely depend on the ability to correctly
differentiate malignant from benign nodules. A prospective estimation of which nodules are of
high risk to represent or develop into a malignancy, and therefore requiring more close fol-
low-up or intense diagnostic work-up as opposed to nodules that are of very low risk, is of cru-
cial importance to make screening programs efficient for a number of reasons including
burden of radiation dose, psychological load of the screening subjects and financial expenses.
This problem has been addressed by the management guidelines published by the American
College of Radiologists (ACR), called Lung-RADS. Nodules with benign appearance and very
low risk (categories 1 and 2) are differentiated from equivocal or suspicious nodules (catego-
ries 3, 4A and 4B) [6]. Lung-RADS and similar recommendations [7–9] have in common that
they use nodule type, nodule size and growth rate to select nodules that are malignant or at
risk to develop into a malignancy. A number of other risk prediction models rather focus on
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the selection of individuals being at risk for developing a lung malignancy [10–13] or estimate
the malignancy probability using both, clinical factors and nodule characteristics [7, 14–15].
The computer model that was evaluated in the following study also uses both a number of
nodule characteristics but also non-nodular CT imaging findings and further on considers a
number of subject related demographic factors [16]. This model is thus far the only published
malignancy risk prediction model that was mathematically modeled based on the findings of
an actual lung cancer screening trial [17]. Whereas other models use fixed thresholds for nod-
ule size this model applies hazard ratios for various parameters that have been derived from
the Pan-Canadian Early Detection of Lung Cancer Study (therefore the name PanCan model).
The model was externally validated using the British Columbia Cancer Agency (BCCA) cohort
and demonstrated a good performance with an area under the receiver-operator-characteris-
tics curve (AUC) of> 0.900 to discriminate malignant from benign nodules [16]. An external
second evaluation study used the cohort of the Danish Lung Cancer Screening Trial (DLCST)
and found an AUC of 0.834 [18]. The difference in results between the two external validation
studies can be explained by the fact that the performance of such risk prediction models are
considerably influenced by the type of nodule annotation protocol (e.g., how many small,
most likely benign nodules were included), the prevalence of malignancy and the underlying
screening population.
In contrast to mathematical risk prediction models, radiologists use a rather complex sys-
tem of visually accessible morphological information when determining the malignancy risk
of pulmonary nodules, such as internal nodular and external perinodular characteristics of the
lung parenchyma in addition to nodule diameter, upper lobe location and nodule type. No
studies thus far have investigated the difference in performance between the PanCan model
and human observers. The purpose of our study was to compare the PanCan model with
human observer performance for the prediction of malignancy risk of screen-detected
nodules.
Methods
Materials
For this retrospective study, we used anonymized CT scans from the Danish Lung Cancer
Screening Trial [19]. Approval by the Ethics Committee of Copenhagen County as well as
informed consent of all participants were available. In the DLCST, two experienced chest
radiologists had separately annotated nodules ( 3 mm) in CT scans with respect to size and
location, based on visual assessment and manual diameter measurements [19]. Follow-up
information with respect to presence of histologically proven malignancies was available for a
follow up of 9 years. Malignancies had a medium diameter of 15 mm (range 4 to 93 mm) on
the first scans they had been annotated.
For the observer study a case-cohort study design was used. A study-group of 300 partici-
pants was selected from the complete screening data set under the following conditions: The
study group included all 60 participants with at least one malignant nodule that had been
found in the complete DLCST (group 1), 120 participants with at least one benign nodule ran-
domly selected from the whole screening dataset (group 2), and 120 participants also randomly
selected from the whole screening dataset but under the condition that they showed at least
one benign nodule with a diameter in the range of 3 to 16 mm with a preference for lesions
larger than 10 mm (group 3).
Group 1 consisted of the CT scans on which the malignant nodules had been annotated
first. In participants with multiple malignant lesions, one malignant nodule was randomly
selected. Group 2 consisted of baseline CT scans with benign nodules of all size ranges being
Malignancy risk in pulmonary nodules: Observers versus computer
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reflective of lesions seen in a screening cohort. Group 3 consisted of baseline CT scans with
benign nodules with a medium size larger than seen in the whole cohort but matching in size
more closely to the malignant nodules.
Two size-matched nodules that had been classified as benign during the screening rounds
developed into malignancies during the follow-up period of 9 years, their status was therefore
changed accordingly resulting in a final group of 62 malignancies, 120 random benign and 118
size-matched benign nodules.
CT acquisition
All CT scans were performed using volumetric acquisition (16 rows Philips Mx 8000, Philips
Medical Systems, Eindhoven, The Netherlands) and a low-dose protocol (120 kV, 40 mAs)
with a section collimation of 16 x 0.75 mm, pitch 1.5 and rotation time 0.5 s. The scans were
obtained after full inspiration and without the use of contrast. Images were reconstructed with
thin (1 mm) sections and a sharp filter algorithm (kernel D) [19].
Readers and image viewing
Eleven observers assessed the nodules in random order, using a computer vision tool (CIRRUS
Observer, Diagnostic Image Analysis Group, RadboudUMC, Nijmegen, The Netherlands) that
allowed for interactive viewing of high quality CT sections in all 3 projections (axial, coronal
and sagittal). The CT data were preloaded and displayed using a zoomed view of each nodule
to shorten the search process, however, observers could scroll and review the complete CT if
warranted. They were instructed to give a malignancy probability score to each nodule on a
scale of 0 to 100, where a score of 0 would indicate that all nodules that looked like this particu-
lar nodule would be benign according to the observer and a score of 100 would indicate that
all similar looking nodules would be malignant according to the observer. The observers
assessed the malignancy score on the basis of visual analysis of nodule morphology. Judgment
was left to the readers’ discretion and no specific criteria were given being suggestive for
malignancy.
Subsequently, the observers scored the presence of certain morphological features for each
nodule according to a predefined list. This list included the following items: single bubble,
multiple bubbles, airbronchogram, bulla with thickened wall, spiculation, lobulation, ill-
defined border, well-defined border, demarcation by interlobular septa, attachment to a vessel,
pleura or fissure, retraction of pleura or fissure, and distortion of surrounding lung architec-
ture. Scoring the morphology features was not mandatory, however, if they decided to score
nodule morphology, they were urged to do so for all nodules. Prior to scoring the actual study
group, 15 example cases were presented to the observers, in order to get familiar with the soft-
ware, nodule scoring method and the morphological features.
The observer group consisted of four board certified radiologists with > 10 years of experi-
ence in reading chest CTs and/or intense research training with respect to interpreting screen-
detected nodules, five radiology residents and two pulmonologists from eight institutions in
five countries. The first group of the four board certified radiologists formed the group of
observers of higher experience as opposed to the remaining seven observers.
PanCan computer model
We used the full model (2b), which determines the malignancy probability score based on the
parameters sex, age, family history of lung cancer, emphysema, nodule size, nodule type, nod-
ule location, nodule count and spiculation. Additionally, performance of the parsimonious
model (1b) was assessed, which includes a limited number of input parameters such as sex,
Malignancy risk in pulmonary nodules: Observers versus computer
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nodule size, nodule location and spiculation [16], thus leaving out age, family history, emphy-
sema, nodule type and nodule count. Family history of lung cancer pertained to parents or sib-
lings. Presence of emphysema was dichotomous and not corresponding to the degree of
emphysema. Nodule size was measured as the longest diameter. Nodule count pertained to the
number of additional nodules in the scan. Spiculation was defined as reticular markings of tis-
sue density centered along the border of the nodule. Nodule type, emphysema, spiculation,
and complete calcification were scored by an experienced radiologist (E.S.) [16] as this infor-
mation was not available from the DLCST database. The remaining parameters such as sex,
age, family history, nodule size, location and count were available from the DLCST database.
Completely calcified nodules and perifissural nodules (PFN) were given a malignancy proba-
bility score of 0 according to the model. The latter refer to smoothly defined nodules smaller
than 5 mm in size that are localized on or very close to the interlobar fissure and correspond to
benign intrapulmonary lymph nodes [20].
Statistical analysis
To compare the performance of the PanCan model with each observers’ performance, a multi-
reader multi-case (MRMC) receiver operating characteristic (ROC) analysis was applied using
the PROPROC method [21–23]. Areas under ROC curve (AUCs) of observers and the full
PanCan model were compared twice: a) considering the scores for all malignant and the set of
randomly selected benign nodules, and separately when b) considering the scores for all malig-
nant and the set of size-matched benign nodules. Performance differences were tested using
the Dorfman, Berbaum and Metz method (DBM-MRMC package, version 2.33, http://
perception.radiology.uiowa.edu), which accounts for case, reader, and treatment variance.
Differences in dataset characteristics were compared using chi-square for categorical
parameters and unpaired t-test analyses for continuous variables. A significant difference was
defined at p< 0.05. Morphological nodule features were considered to be present in the final
data analysis when the majority of the observers had scored its presence positively. Differences
in morphological features between malignant and size-matched benign nodules were analyzed
using chi-square analysis. With Bonferroni correction, a significant difference was defined at
p< 0.004. Analyses were performed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA).
Results
Characteristics of subjects, subgroups and nodules as annotated in the screening database are
summarized in Table 1. The time between the CT scan used in this study and the date of diag-
nosis was on average 20.5 months (range 0.3–86 months); the follow-up time for the benign
nodules was on average 121.1 months (range 109.1–126.7 months).
Nodule size, the presence of spiculation, the presence of nodule calcification, and the num-
ber of nodules per scan (nodule count) were statistically significantly different between malig-
nancies and size-matched benign nodules (p = 0.003, p< 0.001, p = 0.001, and p = 0.042,
respectively) as well as between malignancies and randomly selected benign nodules
(p< 0.001, p< 0.001, p < 0.001, and p = 0.004, respectively). Additionally, nodule type
(p< 0.001), nodule location in the upper lobe (p = 0.006), and the presence of emphysema
(p = 0.005) were statistically significantly different between malignancies and randomly
selected benign nodules (Table 1).
Performance of observers versus the computer model
For discriminating randomly selected benign nodules (group 2) from malignant nodules
(group 1), the PanCan model 2b had an AUC of 0.932 and the human observers had an
Malignancy risk in pulmonary nodules: Observers versus computer
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average AUC of 0.910 (range 0.860–0.950); the difference did not achieve significance
(p = 0.184). The four board certified radiologists yielded an averaged AUC of 0.919, whereas
the five radiology residents and two pulmonologists had an AUC of 0.905. Both were not sig-
nificantly different from the computer model (p = 0.366 and p = 0.117, respectively).
Human observers achieved an average AUC of 0.819 (range 0.771–0.881) for differentiating
size-matched benign nodules (group 3) from malignancies (group 1), while the computer
model achieved an AUC of 0.706. The difference between the mean performance of all observ-
ers and the computer model was statistically significant (p< 0.001). The differences between
each individual observer and the computer model were statistically significant for 10 of the 11
observers (range from p< 0.001 to p = 0.022). The board certified radiologists yielded an aver-
aged AUC of 0.844 while the radiology residents and pulmonologists yielded a mean AUC of
0.804, both performances were significantly different from the computer model (p< 0.001
and p = 0.002, respectively).
The parsimonious model achieved an AUC of 0.920 for the randomly selected benign and
0.695 for the size-matched benign nodules. When nodule size was considered as the only input
parameter for the model, the AUC yielded 0.918 for randomly selected benign and 0.687 for
size-matched benign nodules, respectively. Table 2 displays the AUC of each observer, the
AUC averaged over all observers and the AUC of the computer model for the two discrimina-
tion tasks. Fig 1 shows the corresponding ROC curves. Fig 2 shows examples of nodules classi-
fied uniformly by all observers and the computer model, while Fig 3 depicts examples of
nodules for which discrepant risk estimations occurred between the computer model and
observers.
Malignancy probability scores
In the full computer model, the median malignancy probability score was 18.5% (range 0.3%–
85.7%) for malignant nodules, 4.6% (range 0%–67.8%) for size-matched benign nodules, and
Table 1. Characteristics of the nodule groups.
Parameters PanCan model Malignant nodules* Random benign
nodules
Size-matched
benign nodules
Total P value Size-
matched / random †
Number 62 120 118 300
Age in years 62 (52–75) 58 (50–68) 58 (50–69) 59 (50–75) 0.927 / 0.703
Sex: Male; Female 33 (53%); 29 (47%) 59 (49%); 61 (51%) 60 (51%); 58 (49%) 152 (51%); 148
(49%)
0.875 / 0.598
Family history of lung cancer 16 (26%) 21 (18%) 28 (24%) 65 (22%) 0.245 / 0.624
Emphysema 46 (74%) 62 (52%) 87 (74%) 195 (65%) 1.000 / 0.005
Nodule size in mm 15 (4–93); Median: 12 6 (3–16); Median: 5 12 (3–90); Median: 9 10 (3–93); Median: 7 0.003 / <0.001
Nodule Type: Solid; Part-solid;
Non-solid; Perifissural
45 (73%); 10 (16%); 7
(11%); 0 (0%)
107 (89%); 1 (1%); 3
(2.5%); 9 (7.5%)
84 (71%); 11 (9%); 16
(14%); 7 (6%)
236 (79%); 22 (7%);
26 (9%); 16 (5%)
0.137 / <0.001
Nodule Count 1.3 (1–5) 1.85 (1–6) 1.6 (1–4) 1.6 (1–6) 0.042 / 0.004
Nodule Location: Upper Lobe 39 (63%) 50 (42%) 64 (54%) 153 (51%) 0.273 / 0.006
Spiculation 22 (35%) 3 (3%) 7 (6%) 32 (11%) <0.001 / <0.001
Calcified 0 (0%) 24 (20%) 16 (14%) 40 (13%) 0.001 / <0.001
* Percentages or ranges are in parentheses.
† P-value for malignant and size-matched benign nodules / malignant and randomly selected benign nodules. A p-value < 0.05 indicates significance of
difference. Significant differences are indicated in bold. Note that malignant nodules are more often spiculated, have a higher nodule count, and are on
average 3 mm larger than the size-matched benign nodules. Malignant nodules are more often part-solid nodules and located in the upper lobes compared
to the benign nodule groups, while randomly selected benign nodules are mostly small solid nodules.
https://doi.org/10.1371/journal.pone.0185032.t001
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Table 2. Performance of observers and the various computer models (PanCan 1b and 2b) for the discrimination between malignant and benign
nodules for random and size-matched benign nodules versus malignant nodules.
Readers AUC* random nodules P-value AUC size-matched nodules P-value
Observer 1 0.902 0.285 0.797 0.027
Observer 2 0.909 0.346 0.820 0.002
Observer 3 0.936 0.793 0.877 <0.001
Observer 4 0.928 0.903 0.881 0.004
Observer 5 0.930 0.910 0.800 0.009
Observer 6 0.950 0.274 0.771 0.066
Observer 7 0.881 0.049 0.846 <0.001
Observer 8 0.860 0.004 0.783 0.049
Observer 9 0.901 0.073 0.786 0.023
Observer 10 0.896 0.173 0.813 0.005
Observer 11 0.915 0.499 0.830 0.004
Average all 0.910 0.184 0.819 <0.001
Board certified radiologists (1–4) 0.919 0.366 0.844 <0.001
Radiology residents and pulmonologists (5–11) 0.905 0.117 0.804 0.002
PanCan model 2b 0.932 0.706
PanCan model 1b 0.920 0.695
PanCan, size only 0.918 0.687
* AUC randomly selected nodules: area under the receiver-operating-characteristics curve for discriminating malignant from randomly selected benign
nodules. AUC size-matched nodules: area under the receiver-operating-characteristics curve for discriminating malignant from size-matched benign
nodules. P-values refer to comparison with the PanCan model 2b. A significant difference is defined at p-values < 0.05 and significant differences are
indicated in bold.
https://doi.org/10.1371/journal.pone.0185032.t002
Fig 1. Performance of observers and PanCan model. ROC curves of the observers 1–11, the PanCan model 2b, the
PanCan model 1b, and only nodule size as predictor for (A) discriminating randomly selected benign nodules from
malignant nodules on the left, and (B) on the right discriminating size-matched benign nodules from malignant nodules.
Note that in Fig 1A the PanCan model outperforms human observers at a specificity > 80%, while in Fig 1B all human
observers perform better than the PanCan model.
https://doi.org/10.1371/journal.pone.0185032.g001
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0.4% (range 0%–25.9%) for randomly selected benign nodules. For the parsimonious model
the corresponding numbers were 13.6% (range 0.2%–86.7%), 4.4% (range 0%–62.1%), and
0.3% (range 0%–18.1%).
The median probability scores determined by the observers were 50% (range 15%–75%)
for malignant nodules, 5% (range 0%–25%) for size-matched and 2% (range 0%–10%) for ran-
domly selected benign nodules. The distribution of malignancy probability scores for the three
nodule groups per observer and the computer model are depicted in Fig 4.
Morphological characteristics
Seven observers determined the morphological characteristics of nodules. Table 3 displays the
morphological features scored by the observers. Morphological features that were statistically
significantly predictive of malignancy in the majority of the observers were spiculation
(p< 0.001), distortion of surrounding lung parenchyma architecture (p< 0.001) and
Fig 2. Observer agreement for malignancy probability score. Examples of nodules for which observers and the PanCan model
uniformly scored a high or low malignancy probability. For the observers, a threshold of < 25% averaged over all observers was considered a
’low risk’ score, and a threshold of > 60% was considered a ’high risk’ score. For the PanCan model, a threshold of < 6% was considered as
a ’low risk’ score and a threshold of > 30% was considered as a ’high risk’ score. Nodules are displayed in the axial plane. From left to right:
A) Part-solid malignant nodule, 13 mm, observers scored 65%, PanCan 31.9% corresponding to a uniformly true positive score; B) Solid
malignant nodule, 4 mm, observers scored 9.5%, PanCan 0.3%; corresponding to a uniformly false negative score; C) Solid benign
perifissural nodule, 11 mm, observers scored 1.9%, PanCan 0%, corresponding to a uniformly true negative score; D) Part-solid benign
nodule, 27 mm, observers scored 60%, PanCan 30.7%, corresponding to a uniformly false positive score.
https://doi.org/10.1371/journal.pone.0185032.g002
Fig 3. Observer disagreement for malignancy probability score. Examples of nodules for which the PanCan model and the observers
showed conflicting malignancy probability scores. For the observers, a threshold of < 25% averaged over all observers was considered a
’low’ score, and a threshold of > 60% was considered a ’high’ score. For the PanCan model, a threshold of < 6% was considered a ’low’
score and a threshold of > 30% was considered a ’high’ score. Nodules are displayed in axial plane. From left to right: A) Solid malignant
nodule, 15 mm, observers scored 24%, PanCan 35%; B) Pure ground-glass malignant nodule, 9 mm, observers scored 58%, PanCan 4%;
C) Solid benign nodule, 16.5 mm, observers scored 14%, PanCan 37%; D) Part-solid benign nodule, 13 mm, observers scored 65%,
PanCan 14%.
https://doi.org/10.1371/journal.pone.0185032.g003
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retraction of pleura or fissure (p = 0.002). A well-defined border was statistically significantly
predictive of a benign nodule (p< 0.001). Spiculation is the only feature that is included in the
PanCan model 1b and 2b.
Fig 5 shows typical examples of four morphological characteristics that showed significant
differences.
Discussion
Given the large discrepancy between the prevalence of benign and eventually malignant nod-
ules in a screening population, robust methods for risk prediction are mandatory in a screen-
ing program for accurate discrimination of high-risk lesions that require additional work-up
and low-risk lesions requiring none or less intense follow-up. Given the large number of nod-
ules and scans to be evaluated and the influence of observer variability leading to loss of
Fig 4. Malignancy probability score distribution. The distribution of malignancy probability scores of the
observers and the PanCan model are visualized in these box plots for the malignant nodules in the upper
box plot (A), randomly selected benign nodules in the middle box plot (B), and size-matched benign nodules in
the lower box plot (C). Observers and the PanCan model use a different distribution of the scale (0–100). Note
the large variability between observers with respect to mean and range of risk probability estimates.
https://doi.org/10.1371/journal.pone.0185032.g004
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standardization and even potential oversights, application of a computer model for risk predic-
tion appears a very attractive alternative. The PanCan model published in 2013 was the first
mathematical model for predicting the risk of malignancy in screen-detected nodules that
was derived from an actual screening population (the Pan-Canadian Early Detection of Lung
Cancer Study). Subsequently, two external validations confirmed the high performance of
the PanCan model in screening populations [16, 18, 24] one using the BCCA population
(AUC > 0.900) and one the DLCST screening trial (AUC 0.834). One study comparing four
prediction models for the assessment of clinically detected lung nodules found a performance
for the PanCan model of AUC = 0.902, compared to 0.735 for the Veterans Association model
and 0.895 for the Mayo model. The only model achieving a higher AUC was the Herder model
with 0.924 when including information of FDG PET-CT [24].
In a previous study of our research group we had compared the PanCan model to other
management strategies such as National Comprehensive Cancer Network (NCCN) or Lung-
Table 3. Differences in morphological features between malignant and size-matched benign nodules.
Morphology characteristics Malignant nodules n = 62 * Benign size-matched nodules n = 118 * P-value
Single bubble 2 (3%) 1 (1%) 0.236
Multiple bubbles 6 (10%) 3 (3%) 0.037
Airbronchogram 5 (8%) 4 (3%) 0.171
Bulla with thickened wall 4 (6%) 0 (0%) 0.005
Spiculation 20 (32%) 4 (3%) <0.001
Lobulation 7 (11%) 3 (3%) 0.015
Ill-defined border 19 (31%) 25 (21%) 0.161
Well-defined border 10 (16%) 65 (55%) <0.001
Demarcation by interlobular septum 0 (0%) 1 (1%) 0.467
Attachment to vessel 11 (18%) 6 (5%) 0.006
Attachment to pleura 23 (37%) 45 (38%) 0.891
Attachment to fissure 10 (16%) 13 (11%) 0.329
Retraction of pleural or fissure 12 (19%) 6 (5%) 0.002
Distortion of surrounding lung architecture 14 (23%) 7 (6%) <0.001
* Percentages are in parentheses. Only a positive score occurred when four of the seven observers considered “feature being present”. A p-
value < 0.004 was considered to indicate significance of difference. Significant differences are indicated in bold.
https://doi.org/10.1371/journal.pone.0185032.t003
Fig 5. Examples of nodules with morphological characteristics uniformly scored by six or seven observers. Every nodule is
displayed in axial plane. Images show a field of view of 60 x 60 mm, in which the nodule is centered. From left to right: A) Solid malignant
nodule, 13 mm, with spiculation; B) Part-solid malignant nodule, 17 mm, with retraction of a fissure; C) Solid malignant nodule, 30 mm, with
distortion of surrounding architecture; D) Solid benign nodule, 11 mm, with a well-defined border.
https://doi.org/10.1371/journal.pone.0185032.g005
Malignancy risk in pulmonary nodules: Observers versus computer
PLOS ONE | https://doi.org/10.1371/journal.pone.0185032 November 9, 2017 10 / 15
RADS for risk estimation of screen-detected nodules and also found a superiority of PanCan
to the other regimen, with an AUC of 0.874 compared to 0.813 (Lung-RADS, p = 0.003) and to
0.836 (NCCN, p = 0.010) [25].
We therefore were particularly interested in comparing the performance of the PanCan
computer model to human observers, which has never been done before.
To optimize between observer time and acquisition of statistically meaningful data, we used
a case-controlled study set-up. Therefore, our study design has a different prevalence of malig-
nant nodules (~33%) compared to, for example, the NLST (< 3%). Although there is little
research on the effect of prevalence expectation on the performance of observers, the available
research suggests that the effect is minimal [26]. Additionally, this study design is not suited to
be used as external validation of the performance of the PanCan model for a screening cohort
as has been done previously using the BCCN and the Danish lung cancer screening dataset.
In fact, our results confirm the high performance of the PanCan model in a representative
subset of the DLCST baseline population for discriminating malignant from randomly selected
benign nodules. The PanCan model was slightly, yet not significantly superior to the average
human observer performance (0.932 versus 0.910, p = 0.184). Based on this result it can be
concluded that the PanCan model represents a very valuable tool that is equally effective for
discriminating high-risk from low-risk screen-detected nodules as radiologists with varying
experience.
Our results underline the importance of size for predicting malignancy risk [27]. In fact,
using only size as the single indicator provided comparable AUCs as using the full PanCan
model, as illustrated in Fig 1. For the task of differentiating malignant from benign nodules of
similar size, the observers as well as the PanCan model achieved a substantially lower perfor-
mance than for the task of discriminating malignant from randomly selected benign nodules.
This can be explained by the fact that increasing size alone represents a very strong risk factor.
However, by taking visually accessible morphological aspects other than size and spiculation
into account, the human observers achieved a superior performance to the PanCan model for
this dataset (AUC 0.819 and 0.706, respectively, p< 0.001). The morphological characteristics
that were rated with different frequency in malignant and benign lesions were related to bor-
der characteristics (spiculation and well-defined border) and interference of the nodule with
the perinodular lung architecture (retraction of the pleura or fissure, distortion of the sur-
rounding architecture). While it can be assumed that these features did have an impact on the
observers’ judgment, the findings that make an observer rate a lesion as suspicious are most
likely more complex. Similar results were reported by Chung et al. [28] who reported a signifi-
cant increase of correctly updated subsolid lesions to Lung-RADS category 4B, which repre-
sents the most suspicious and highest risk category based on visual analysis. Similar to our
results, inter-reader variability was substantial and observer data did not allow to pinpoint a
single group of morphological features being significantly predictive.
Although visual analysis of morphology apparently provides very useful information with
substantial discriminative power, none of the features were completely discriminative, and
there seems to be substantial observer variability as indicated by the substantial inter-reader
variability for the malignancy probability scores. The latter was demonstrated by one observer
(number 6) to an extreme: while achieving the best performance for discriminating malignan-
cies versus randomly selected benign nodules, the observer demonstrated the poorest perfor-
mance for discriminating malignancies from size-matched benign nodules. In general, more
experienced observers achieved a higher performance than less experienced observers (AUC
0.919 vs. 0.905 for random subset; 0.844 vs. 0.804 for size-matched subset).
Another way to further improve the model’s performance could be to include nodule
growth between scans obtained at different time points. Several studies have shown [29–30]
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that lesion growth over time is the most important and powerful predictor of nodule malig-
nancy. Recently Horeweg et al. demonstrated that volume doubling time (VDT) can be used
as an additional feature to individualize management of intermediate-sized nodules (5–10
mm). Using the database of the Dutch-Belgian lung cancer screening trial, the authors
reported a malignancy risk of 0.8% for a volume doubling time (VDT) of 600 days, a risk
of 4% for a VDT of 400–600 days and a risk of 9.9% for a VDT of 400 days [31].
It has to be noted that the observer probability scores on a scale from 0 to 100 cannot be
directly transferred to the probability estimates of the PanCan model. Some observers used
only the lower end of the range between 0 and 100, while others used a more wide-spread dis-
tribution. Following the PanCan model output thresholds as described by Tammemagi et al.
[32], a score of< 6% represents a low-risk lesion triggering annual repeat screening, an inter-
mediate score between 6% and < 30% triggers a rescreen in 3 months and a score of 30%
indicates a high-risk lesion requiring more intense and possibly invasive diagnostic work-up.
The PanCan model rarely achieves scores beyond 50%. There is an inherent discrepancy in the
process of risk estimation of a logical but rigid mathematical model and the intuitive but vari-
able visual analysis of human observers. Whereas a direct comparison of the scores does not
lead to meaningful conclusions, the ROC statistical analysis we used sufficiently considered
the relative distribution of the scores and therefore allowed for comparing the performances of
observers and the PanCan model.
Our study has limitations. In the size-matched experiment, we tried to match the benign
nodules in size to the malignant nodules as close as possible but perfect matching was not pos-
sible. As a result, the mean diameter of the malignant lesions was 3 mm larger than the mean
of the benign nodules. However, while introducing a bias, it affected both observers and math-
ematical model in the same direction.
Another limitation refers to the different inclusion criteria of the PanCan model and the
DLCST: perifissural and calcified nodules were specifically excluded in the PanCan model
because of most likely being benign. In the DLCST trial, however, calcified and perifissural
nodules were included as solid nodules. Both, calcified and perifissual nodules in the group of
randomly selected and size-matched benign nodules were therefore assigned a score of 0% in
our study, to account for this design difference.
Furthermore, our dataset comprised a relatively small number of lung cancers (62 in total),
although we included all participants with malignant nodules annotated in the DLCST.
Finally, inter-observer variability was not further quantified, however it’s well reflected in
the variable AUC of the observers and the large variability of risk scores (Fig 4), as can be
expected with a large number of observers.
In conclusion, the PanCan risk prediction model and human observers perform equally
well for differentiating malignant from randomly selected benign screen-detected pulmonary
nodules, underlining the large potential of computer based risk estimation to trigger nodule
management in population based screening studies. Human observers, however, significantly
outperform the PanCan model for differentiating malignant from size-matched screen-
detected benign nodules suggesting that integration of additional morphological characteris-
tics, such as pleural retraction and perinodular lung parenchyma distortion, used by the
human observers is very likely to lead to further improvement of computer based risk predic-
tion models.
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